



The relative strengths and weaknesses of Fulgent Genetics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Fulgent Genetics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 71% points. The greatest weakness of Fulgent Genetics Inc is the variable Liabilities, Current, reducing the Economic Capital Ratio by 6.5% points.

The company's Economic Capital Ratio, given in the ranking table, is 274%, being 114% points above the market average of 160%.

| Input Variable                        | Value in 1000 USD | Output Variable             | Value in 1000 USD |
|---------------------------------------|-------------------|-----------------------------|-------------------|
| Assets, Current                       | 523,616           | Assets                      | 700,461           |
| Assets, Non-Current                   | 4,144             | Liabilities                 | 131,074           |
| Cost of Goods and Services Sold       | 89,807            | Expenses                    | 208,440           |
| Depreciation, Depletion, Amortization | 0                 | Revenues                    | 423,238           |
| General and Administrative Expense    | 15,215            | Stockholders Equity         | 569,387           |
| Goodwill Impairment Loss              | 0                 | Net Income                  | 214,310           |
| Intangible Assets                     | 0                 | Comprehensive Net Income    | 214,602           |
| Labor Expense                         | 0                 | BaseVar                     | 731,996           |
| Liabilities, Current                  | 130,115           | ECR before LimitedLiability | 250%              |
| Long Term Liabilities                 | 582               | Economic Capital Ratio      | 274%              |
| Operating Costs and Expenses          | 0                 |                             |                   |
| Other Assets                          | 132,502           |                             |                   |
| Other Compr. Net Income               | 292               |                             |                   |
| Other Expenses                        | 76,886            |                             |                   |
| Other Liabilities                     | 377               |                             |                   |
| Other Net Income                      | -488              |                             |                   |
| Other Revenues                        | 423,238           |                             |                   |
| Property Plant and Equipment          | 40,199            |                             |                   |
| Research And Development Expense      | 11,580            |                             |                   |
| Selling and Marketing Expense         | 14,952            |                             |                   |